675-P: Final Outcomes of a Four-Year Effort to Support, Scale, and Sustain the National Diabetes Prevention Program

Abstract

CDC’s State and Local Public Health Actions 1422 Cooperative Agreement funded 17 states and 4 large cities for four years to develop and sustain the National Diabetes Prevention Program (National DPP) lifestyle change program (LCP) by implementing comprehensive environmental, health system, and community-clinical linkage strategies for populations at high-risk for type 2 diabetes. Objectives: (1) Describe health system and community-clinical linkage strategies implemented; (2) share findings from baseline to year 4, and (3) highlight key facilitators and barriers to scale and sustain the National DPP. Qualitative and quantitative data were analyzed from awardees’ annual performance reports and health impact statements. Performance measure data from baseline to year 4 were analyzed to determine year-to-year percent change. Qualitative data from awardees were analyzed to identify barriers and facilitators to implementing activities, and understand how barriers were overcome. Recipients and sub-awardees worked with partners across key sectors to implement evidence-based strategies and increase coverage and referral policies to promote engagement in CDC-recognized LCPs. Outcomes from baseline to year 4 will be shared on reach of diabetes prevention media campaigns, the number of people in health systems identified as having prediabetes, the number of health systems engaging community health workers, and the total number of people enrolled in CDC-recognized diabetes prevention programs. Barriers and facilitators to implementation of the National DPP will also be shared. Key lessons learned from SLPHA-1422 include the importance of leveraging existing programs and infrastructure (i.e., SPHA-1305 resources) to scale and sustain the National DPP, establishing strong partnerships across sectors, providing on-going training and technical assistance to recipients and prioritizing enrollment of participants in CDC-recognized LCPs. Disclosure Y. Mensa-Wilmot: None. A. Mensa-Kwao: None. K.D. Farris: None. S. Bowen: None. S. Thummalapally: None. M.D. Murphy: None. G.E. Rutledge: None.